Guoqing Yang1, Juming Lu, Changyu Pan. 1. Department of Endocrinology, General Hospital of the PLA, Beijing 100853, China. yanggq@public.bta.net.cn
Abstract
OBJECTIVE: An increased plasma homocysteine level is an important risk factor for vascular disease in the general population. However, the role of hyperhomocysteinemia in the development of type 2 diabetic retinopathy (DR) is still unknown. Therefore, our aim was to determine the relationship between the fasting plasma homocysteine (Hcy) levels and the presence of diabetic retinopathy in patients with type 2 diabetes. METHODS: The study group consisted of 55 cases of type 2 diabetic patients (DM); 19 healthy persons served as control (CON, 12 men and 7 women). The DM group were subdivided into a group without diabetic complications (NDC, 39 cases, 17 men and 22 women) and a group with DR (16 cases, 8 men and 8 women). The renal function and the ratio of albumin/creatinine (Alb/Cr) were within normal range in all the subjects. The presence and the grade of retinopathy were determined by an ophthalmologist. Plasma total Hcy (tHcy) was measured by automated high-performance liquid chromatography (HPLC) with reverse phase separation and fluorescence detection. RESULTS: Plasma tHcy levels were significantly different among DR, NDC and CON groups (F = 2.405, P = 0.031). Plasma total Hcy was significantly higher in DR group [(14.7 +/- 5.28) micromol/L] than in NDC [(11.3 +/- 4.94) micromol/L] and CON group [(9.65 +/- 2.66) micromol/L]. There was no difference between NDC group and CON group. In DR group, plasma tHcy was significantly higher in proliferative diabetic retinopathy (PDR) group than that in background diabetic retinopathy (BDR) group (t = 2.405, P = 0.031). Hyperhomocysteinemia was defined as tHcy level > 14.97 micromol/L and was seen in 4 patients in PDR group, the rate being significantly higher than that in BDR group. CONCLUSION: It is suggested that hyperhomocysteinemia may be a risk factor for the development and progression of type 2 diabetic retinopathy.
OBJECTIVE: An increased plasma homocysteine level is an important risk factor for vascular disease in the general population. However, the role of hyperhomocysteinemia in the development of type 2 diabetic retinopathy (DR) is still unknown. Therefore, our aim was to determine the relationship between the fasting plasma homocysteine (Hcy) levels and the presence of diabetic retinopathy in patients with type 2 diabetes. METHODS: The study group consisted of 55 cases of type 2 diabeticpatients (DM); 19 healthy persons served as control (CON, 12 men and 7 women). The DM group were subdivided into a group without diabetic complications (NDC, 39 cases, 17 men and 22 women) and a group with DR (16 cases, 8 men and 8 women). The renal function and the ratio of albumin/creatinine (Alb/Cr) were within normal range in all the subjects. The presence and the grade of retinopathy were determined by an ophthalmologist. Plasma total Hcy (tHcy) was measured by automated high-performance liquid chromatography (HPLC) with reverse phase separation and fluorescence detection. RESULTS: Plasma tHcy levels were significantly different among DR, NDC and CON groups (F = 2.405, P = 0.031). Plasma total Hcy was significantly higher in DR group [(14.7 +/- 5.28) micromol/L] than in NDC [(11.3 +/- 4.94) micromol/L] and CON group [(9.65 +/- 2.66) micromol/L]. There was no difference between NDC group and CON group. In DR group, plasma tHcy was significantly higher in proliferative diabetic retinopathy (PDR) group than that in background diabetic retinopathy (BDR) group (t = 2.405, P = 0.031). Hyperhomocysteinemia was defined as tHcy level > 14.97 micromol/L and was seen in 4 patients in PDR group, the rate being significantly higher than that in BDR group. CONCLUSION: It is suggested that hyperhomocysteinemia may be a risk factor for the development and progression of type 2 diabetic retinopathy.
Authors: Preethi S Ganapathy; Richard L Perry; Amany Tawfik; Robert M Smith; Elizabeth Perry; Penny Roon; B Renee Bozard; Yonju Ha; Sylvia B Smith Journal: Invest Ophthalmol Vis Sci Date: 2011-07-25 Impact factor: 4.799
Authors: B Renee Bozard; Preethi S Ganapathy; Jennifer Duplantier; Barbara Mysona; Yonju Ha; Penny Roon; Robert Smith; I David Goldman; Puttur Prasad; Pamela M Martin; Vadivel Ganapathy; Sylvia B Smith Journal: Invest Ophthalmol Vis Sci Date: 2010-01-06 Impact factor: 4.799
Authors: Preethi S Ganapathy; Brent Moister; Penny Roon; Barbara A Mysona; Jennifer Duplantier; Ying Dun; Tracy K V E Moister; Marlena J Farley; Puttur D Prasad; Kebin Liu; Sylvia B Smith Journal: Invest Ophthalmol Vis Sci Date: 2009-04-08 Impact factor: 4.799
Authors: Amany Tawfik; Shanu Markand; Mohamed Al-Shabrawey; Jamie N Mayo; Jason Reynolds; Shawn E Bearden; Vadivel Ganapathy; Sylvia B Smith Journal: Am J Pathol Date: 2014-07-10 Impact factor: 4.307